USDA Issues Draft Guidance for Microorganism Permit Applications

On March 23, 2023, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) announced that it had issued a draft guidance document describing information requirements and procedures applicants should follow when submitting permit applications for microorganisms developed using genetic engineering.

USDA’s biotechnology regulations under 7 CFR Part 340, recently updated in 2020, are the rules under which the agency has regulated the interstate movement and environmental release of organisms that may pose a plant pest risk. According to the APHIS website, the 2020 revisions enable the Agency “to regulate organisms developed using genetic engineering for plant pest risk with greater precision and [to] reduce regulatory burden for developers of organisms that are unlikely to pose plant pest risks”. This rule has primarily been used to cover the field testing and outdoor growth of GMO (transgenic) plants, but the regulation also covers certain microorganisms that have been genetically modified and which might pose a risk as a plant pest. Of the 1,540 entries in APHIS’s database of permit applications and notifications it has received under this regulation, 75 are identified as “bacteria” (of various species) and 11 for “fungi” (as well as 66 for “viruses”).

The draft Guide for Submitting Permit Applications for Microorganisms Developed using Genetic Engineering Under 7 CFR part 340 is available for downloading on the APHIS Biotechnology Regulatory Services Guidance webpage. Interested parties may view and submit comments at https://www.regulations.gov/docket/APHIS-2023-0030/document. The Agency will consider all comments submitted through May 22, 2023, after which the Agency will finalize the Guide.

The guidance document consists of introductory sections describing the Part 340 Rule and the organisms it might cover. After describing the process by which permit applications are to be submitted, the Guide describes the specific information needed for applications either for interstate movement or for environmental release (e.g. field testing or other experimentation) of modified microorganisms that might be subject to the rule. In either case, the applicant must submit detailed information on the organism, its taxonomy, how it was constructed, and its genotype and expected phenotype. The guidance for environmental use is more detailed, and asks applicants to provide information on the site of the proposed field test, the planned procedures to confine the organism to the test site, procedures for detection and monitoring of the organism and its possible spread beyond the test site, and procedures for devitalization of the organism at the conclusion of the trial. For both types of permit applications, at least one Standard Operating Procedure must be submitted that describes procedures for how the organism will be contained during movement between sites, and how it would be confined during any field release.

Although oversight over modified agricultural microorganisms has only been a minor application of the Part 340 regulation since its inception, it is important because it could potentially cover the types of microorganisms that are being developed for various agricultural purposes, including potential biostimulants, organisms promoting improved nutrient uptake, plant pest biocontrol agents, and others, at a time when many companies and research labs are indeed exploring uses of microorganisms for such purposes. In addition, certain microbes regulated under this rule could also be subject to review or regulation by the Environmental Protection Agency under the pesticide law FIFRA or the chemical law TSCA.

D. Glass Associates, Inc. is a consulting company specializing in government and regulatory affairs support for renewable fuels and industrial biotechnology. David Glass, Ph.D. is a veteran of over thirty-five years in the biotechnology industry, with expertise in industrial biotechnology regulatory affairs, U.S. and international renewable fuels regulation, patents, technology licensing, and market and technology assessments. In addition to his work as a consultant assisting industrial biotechnology companies prepare for and comply with government regulations, he has served as Director of Regulatory Affairs for Joule Unlimited Technologies and Vice President of Government and Regulatory Affairs for BioTechnica International. Dr. Glass has extensive experience with the biotechnology regulations of the U.S. EPA and other agencies, and has coordinated or assisted in the preparation and submission of 18 successful Microbial Commercial Activity Notices and several other biotechnology submissions in the U.S. and other countries. Dr. Glass holds a B.S. in Biological Sciences from Cornell University and a Ph.D. in Biochemical Sciences from Princeton University.

Advertisement

Working with Partners and Customers on Industrial Biotechnology Regulatory Strategies: Part 4

This is the fourth and final entry of a series of posts in which I’ve presented an expanded version of a presentation I made in May 2022 at the AIChE 5th Commercializing Industrial Biotechnology conference in San Diego, discussing strategies for planning and implementing regulatory submissions for industrial biotechnology projects involving a partnership with another party. In the first entry, I summarized the different types of relationships that might govern industrial biotechnology commercialization efforts, and presented a summary of the types of information typically needed in biotechnology regulatory submissions. In the second post, I discussed the issues and challenges that might be faced in preparing regulatory dossiers for these different types of commercial partnerships. The third post addressed issues that might arise when the commercial project will take place in a foreign country, under the jurisdiction of a possibly unfamiliar regulatory agency. Today’s post will complete the series with some recommendations for approaching regulatory submissions for projects involving commercial partners.

Recommendations

Although these various scenarios offer differing challenges, they nevertheless share enough similarities so that I can offer some general recommendations for planning regulatory submissions for such collaborative projects.

First is the advice I give to any company contemplating the need for regulatory approvals, which is to plan ahead. It is wise to begin internal planning at least 9-12 months before intended start date, where possible, perhaps longer if the collaboration will be international. Most biotechnology regulations specify agency review periods of at least 90 days, although some can be quite a bit longer, and this of course varies from country to country. This advice applies not only to internal planning but also to your communications with the partner regarding the likely regulatory roadmap. It is necessary to involve your third party partners as early as possible in the process, and to set clear expectations from the outset.

Along these lines, it is important to clearly establish the responsibilities of the respective parties in developing the information and data needed in the regulatory process. In some cases this can be addressed in the partnership agreement between the parties, in which the roles and responsibilities of the partners will often be specified. But you need to make clear to the partner as early as possible what your expectations or needs may be for the information and other assistance you’ll need from them,

Communications can be difficult where the third party is a customer or licensee: be sure the third party understands the need and value of the regulatory process. Some partners for industrial biotech projects may operate in industries or countries where there is little or no regulation, or in most cases the partners will not be familiar with the way biotechnology processes are regulated. You should be sure they understand and accept the necessity and the legitimacy of the regulatory process, and are committed to helping you achieve success. Finally, as mentioned above, it will often be necessary to explain agency policies towards company confidential information, to ensure your partner that their information will be protected.

This is the final installment in this 4-post report. To obtain a PDF copy of the entire report, in the form of a white paper, please contact David Glass at dglass@dglassassociates.com.

D. Glass Associates, Inc. is a consulting company specializing in government and regulatory affairs support for renewable fuels and industrial biotechnology. David Glass, Ph.D. is a veteran of over thirty-five years in the biotechnology industry, with expertise in industrial biotechnology regulatory affairs, U.S. and international renewable fuels regulation, patents, technology licensing, and market and technology assessments. In addition to his work as a consultant assisting industrial biotechnology companies prepare for and comply with government regulations, he has served as Director of Regulatory Affairs for Joule Unlimited Technologies and Vice President of Government and Regulatory Affairs for BioTechnica International. Dr. Glass has extensive experience with the biotechnology regulations of the U.S. EPA and other agencies, and has coordinated or assisted in the preparation and submission of 18 successful Microbial Commercial Activity Notices and several other biotechnology submissions in the U.S. and other countries. Dr. Glass holds a B.S. in Biological Sciences from Cornell University and a Ph.D. in Biochemical Sciences from Princeton University.

Lots of recent action on regulatory agency public comment periods

The early weeks of the new year are seeing a lot of activity from several U.S. government agencies having oversight over industrial biotechnology, food biotechnology and renewable fuels. Several public comment periods are now underway on proposed regulations, agency initiatives, or requests for information, some of which address potentially important issues for certain applications of advanced biotechnology. These activities include the following:

Biotechnology Coordinated Framework. In what might potentially be a broad, far-reaching inquiry, the Office of Science and Technology Policy (OSTP) announced in December 2022 a Request for Information entitled “Identifying Ambiguities, Gaps, Inefficiencies, and Uncertainties in the Coordinated Framework for the Regulation of Biotechnology”. First issued in 1986 and updated in 2017, the “Coordinated Framework” represents the U.S. government’s approach to regulating the diverse products that can be developed using biotechnology, and includes regulations administered by the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA) and the Department of Agriculture (USDA). In a September 2022 Executive Order issued by President Biden, OSTP has been charged with soliciting information from stakeholders on ambiguities and gaps in the framework that might affect the efficient development and regulatory approval for biotech products. A public comment period is open until February 3, 2023. (Another RFI was also issued as a result of this Executive Order, “Request for Information: National Biotechnology and Biomanufacturing Initiative”, but its comment period is expiring on January 20, 2023). The RFI listed 7 specific questions on which comment is solicited, the most important of which are the identification of supposed gaps or ambiguities in the Framework and consideration of their impact, including economic impact, on biotechnology product development.

Animal Feed Ingredients. It is the FDA Center for Veterinary Medicine (CVM) that has regulatory responsibility for animal foods and food ingredients, but as readers of this blog know, FDA CVM also participates in a parallel program for review of feed ingredients maintained by the Association of American Feed Control Officials (AAFCO). The AAFCO program provides an alternative path for review and approval of novel feed ingredients, but CVM staff has conducted the technical reviews of products submitted to AAFCO under this program. In a December 2022 announcement, FDA announced that it will be holding a virtual public hearing on February 9, 2023, to discuss FDA’s role in the AAFCO feed ingredient process. The agency will also entertain public comments on this topic through March 9, 2023. The agency listed the following issues on which comment is solicited:

  1. What steps can FDA take to improve stakeholder understanding of FDA’s engagement with AAFCO’s feed ingredient definition process and better communicate this information with the public? 
  2. What changes to FDA’s role in AAFCO’s feed ingredient definition process would be helpful to stakeholders and why?
  3. If FDA made a list of AAFCO feed ingredient definition requests publicly available, where would stakeholders prefer to find such a list and what information would stakeholders like to see with such a list? 
  4. What do stakeholders view as successful or valuable in FDA’s continued participation as the scientific reviewers for new AAFCO feed ingredient definitions?

Renewable Fuel Standard. On December 1, 2022, EPA announced a proposed rule to establish the required Renewable Fuel Standard (RFS) volumes and percentage standards for 2023, 2024, and 2025. The proposed rule also included a series of modifications to strengthen and expand the RFS program. The RFS is the federal government’s major program promoting the use of renewable and low-carbon fuels for automotive and aviation use, by establishing yearly mandated volumes for the amounts of such fuels to be sold in the U.S. A public hearing on the rule was held on January 10-11, 2023, but public comments will be entertained until February 10, 2023.

I don’t expect that anything significant will arise from the review of the Coordinated Framework. The previous review of the Framework that took place in the Obama Administration from 2016-2017 resulted only in some clarifications of agency jurisdictions, and (at least to this longtime observer of the government’s biotech policies) did not break any new ground or result in any new or relaxed regulations (it is not clear to me whether the USDA’s 2020 revised biotechnology rule at 7 CFR 340, the so-called SECURE Rule, which was years in the making, could be directly attributed to the 2017 updating of the Framework).

However, there are certainly some areas of potential overlap which are worth comment. One issue of longstanding concern is the possibility that genetically modified microbial soil inoculant products could be subject both to the USDA biotechnology rule and EPA regulations under the Toxic Substances Control Act. Another topic has to do with the regulation of certain animal feed ingredients that are, or include, inactivated microbial biomass arising from industrial fermentations; a topic that has long been of concern to me (as described in earlier blog posts), and where the cooperation between FDA CVM and AAFCO has contributed to long review times and inefficient reviews of potential products. Another area that may potentially draw some public comment is the emerging oversight regime for cell-based or plant-based meat products, also a topic on which I’ve previously commented in this blog. It’s worth noting that the first successful approval was achieved in November 2022 under FDA’s Pre-Market Consultation program for review of foods made from cultured animal cells.

D. Glass Associates, Inc. is a consulting company specializing in government and regulatory affairs support for renewable fuels and industrial biotechnology. David Glass, Ph.D. is a veteran of over thirty-five years in the biotechnology industry, with expertise in industrial biotechnology regulatory affairs, U.S. and international renewable fuels regulation, patents, technology licensing, and market and technology assessments. More information on D. Glass Associates’ regulatory affairs consulting capabilities, and links to some of Dr. Glass’s prior presentations on biofuels and biotechnology regulation, are available at www.dglassassociates.com. The views expressed in this blog are those of Dr. Glass and D. Glass Associates and do not represent the views of any other organization with which Dr. Glass is affiliated. 

Review of Recent EPA TERAs for Outdoor Research with Modified Microorganisms

In a recent blog post, I summarized submissions to the U.S. Environmental Protection Agency for outdoor field tests of genetically modified microorganisms under the TERA (TSCA Environmental Release Application) provisions of the Agency’s biotechnology regulations under the Toxic Substances Control Act (TSCA). In today’s post, and the ones that will follow, I’ll briefly describe the most recent TERAs, beginning with those filed with EPA since 2014.

As previously described, the commercial use of modified microorganisms for purposes subject to TSCA jurisdiction might be subject to EPA’s biotechnology regulations under TSCA. Commercial use or importation into the U.S. of certain modified microorganisms (i.e., “new organisms” containing coding nucleic acids from more than one taxonomic genus) for purposes that are within TSCA’s jurisdiction require prior submittal to EPA of a Microbial Commercial Activity Notice (MCAN). Applications potentially subject to TSCA jurisdiction include production of industrial chemicals (including biofuels and certain enzymes), as well as uses of microorganisms for environmental purposes such as bioremediation and non-pesticidal agricultural uses. The latter category might include plant inoculants to promote nitrogen fixation, soil amendments, biofertilizers and plant biostimulants. Although R&D activities are largely exempt from TSCA oversight, the biotechnology regulations require that research involving “new microorganisms” in the open environment (outside a “contained structure”) require EPA review before the research can be conducted, through the filing of a TERA.  The TERA process provides an expedited review procedure for small-scale field tests and other outdoor R&D uses of new organisms, with applicants required to submit TERAs at least 60 days in advance of the proposed activity. See my earlier blog post for more background on TERAs, their data requirements, and the review process.

As I reported in the earlier post, there has only been limited experience with TERAs since the biotechnology rule was put into place in 1997.   According to EPA’s websites, there have been about 40 TERAs submitted for open environmental use of engineered microorganisms, and all but four of these proposals were approved. I have reviewed the TERAs filed prior to 2014 in previous posts, and in today’s post I will describe three TERAs filed in 2014 and 2015.

TERAs R-15-0001 and R-15-0002 were submitted by Elemental Enzymes Ag and Turf, LLC. According to the company’s website, Elemental Enzyme creates “enzyme, peptide and natural solutions that improve plant health, performance and yield” by applying cross-disciplinary scientific solutions to complex agricultural problems. Their products and processes are “applied through seed treatment, in-furrow soil treatments, foliar applications, tree injection, fertilizer impregnation and fertigation”. These TERAs proposed a series of field tests of a technology in which select beneficial enzymes were expressed on the outermost layer (the exosporium) of spores of Bacillus thuringiensis subsp. Israelensis. The company was developing this technology in the expectation that such spores would be an efficacious way to deliver enzymes directly to crop plants. B. thuringiensis is of course a species well-known for different subspecies that express specific insect toxins, and which have been used as natural biopesticides against lepidopteran and coleopteran pests for many years. However, Elemental Enzymes was not making use of that trait, and in fact their strain of B. thuringiensis subsp. Israelensis was missing the genes needed to encode the insect toxin.

The company created multiple strains of modified B. thuringiensis subsp. Israelensis, each expressing a different plasmid-encoded enzyme. The eight enzymes expressed by these strains were endo-1,4-β-glucanase, β-1,3 glucanase, phytase, chitosanase, protease 2, alkaline phosphatase 4, lipase EstA,  and phosphatidylcholine phospholipase. The strains were to be administered either directly to seed or in-furrow, and field tests were planned in 14 states on a variety of crops including corn, squash, tomatoes and cucumber. The purpose of the trials was to determine if the enzymes imparted beneficial growth-promoting properties to any of the crop plants; monitoring of the modified strains was also contemplated.

It is not known in the public record if these tests were carried out and what the result may have been, and there were no follow-up TERAs submitted for these strains. Today, the company is selling or developing a number of products for agriculture, but spore-delivered growth-promoting enzymes do not appear to be among them.

These TERAs are unique in several ways. They are likely the only submissions to a federal agency for a field test involving spores of genetically modified microorganisms. And the proposed experiments were somewhat unusual in the use of a species known for its pesticidal properties for a purpose unrelated to such properties. These TERAs also appear to have been the first for testing of soil inocula since the nitrogen-fixing experiments under TERAs in 1999-2000, which is of interest given the recent increase in commercial activity towards developing improved seed and soil inoculants to improve crop growth and yield.

TERA R-15-0003 was submitted by the National Institute of Standards and Technology (NIST) on April 30, 2015 for a proposed field test of a modified strain of Saccharomyces cerevisiae. This proposal is also one that is unlike any other TERA that has yet been filed with EPA. The purpose of the proposed field test was to test the ability of a modified yeast strain to serve as a “reference material to support first responder training and workflow evaluation for on-site biological assessment technologies”.  In response to a 2011 report from the Department of Homeland Security, researchers at NIST were developing a program to train first responders how to deal with “suspicious white powder incidents” that might arise from terrorist activity. The goal of this project was to evaluate whether this modified S. cerevisiae strain could be used “as a qualitative and quantitative reference material for microbial abundance measurements” under conditions mimicking a field response to a white powder incident.

The NIST team modified a wild type S. cerevisiae strain to contain a 438 bp fragment from a heterologous organism, Methanocaldococcus jannaschii, a noncoding sequence selected to have minimal homology to the S. cerevisiae sequences, which could be used to detect the microorganism in PCR assays. In the proposed test under the TERA, cells of the modified strain were to be lyophilized and released to the environment in two ways: either fixed on metal coupons which would be placed at different locations around the test site, or released to the atmosphere in a plume at the site. In the first case, the plan was for the researchers to retrieve the metal coupons and obtain microbial samples using swabs, and the samples would then be quantified using qPCR and viable-cell counting. In the second case, clean metal coupons would be used to collect the microorganisms from the plume, and the coupons used as in the first experiment to obtain microbial samples for qPCR and plate counting.

NIST conducted the test in July 2015 and subsequently filed a report with EPA describing the results. The air plume experiment was not carried out due to unforeseen circumstances, but the first experiment with the metal coupons was conducted. The report concluded “Overall, the use of the yeast was a success. Of the 4 detection sites, only 3 sites reported results. One site did not report results due to technical difficulties at the time of testing. All the reporting sites successfully detected the yeast from the samples collected from coupons with yeast”.

These two proposals from several years ago are indicative of the breadth of R&D activity in exploring the uses of modified microorganisms for beneficial uses in the environment. As noted above, the Elemental Enzyme TERAs can be seen as an early harbinger of renewed commercial interest in developing improved microorganisms for non-pesticidal agricultural purposes, and the NIST proposal is an example of how the techniques of modern biotechnology can be applied in innovative and perhaps unexpected ways.

In the blog post that will follow in a few days, I’ll describe another batch of TERAs, including three successful proposals for open-pond field testing of genetically modified algae.

To conclude, I’ll reiterate my earlier comments that the TERA process is well-suited to allow the assessment of the potential risks of proposed environmental uses of modified organisms. The TERA process allows outdoor uses of modified microorganisms to take place in a stepwise fashion under appropriate monitoring and agency oversight, to enable legitimate scientific issues of environmental risk assessment to be addressed with data from actual controlled small-scale environmental use, thus facilitating subsequent risk assessments for larger-scale uses.

D. Glass Associates, Inc. is a consulting company specializing in government and regulatory affairs support for renewable fuels and industrial biotechnology. David Glass, Ph.D. is a veteran of over thirty-five years in the biotechnology industry, with expertise in industrial biotechnology regulatory affairs, U.S. and international renewable fuels regulation, patents, technology licensing, and market and technology assessments. More information on D. Glass Associates’ regulatory affairs consulting capabilities, and links to some of Dr. Glass’s prior presentations on biofuels and biotechnology regulation, are available at www.dglassassociates.com. The views expressed in this blog are those of Dr. Glass and D. Glass Associates and do not represent the views of any other organization with which Dr. Glass is affiliated.

EPA TERAs for Agricultural and Environmental R&D with Modified Microorganisms

In past years on the blog, I’ve written about various aspects of the U.S. EPA regulations under the Toxic Substances Control Act (TSCA) that cover industrial and other uses of genetically modified microorganisms, which in recent years have applied to many commercial biofuel and bio-based chemical projects. Today I’m writing about one aspect of these regulations that cover proposed outdoor research activities of certain modified microorganisms, which might affect not only the open-pond use of modified algae to produce fuels or chemicals, but also proposed field testing of certain agricultural microorganisms intended for non-pesticidal use in the open environment. This is the requirement to obtain prior EPA review and approval of field test plans through submission of a TSCA Environmental Release Application (TERA).  

As previously described, the commercial use of modified microorganisms for purposes subject to TSCA jurisdiction might be subject to EPA’s biotechnology regulations under TSCA. Commercial use of certain modified microorganisms (i.e., “new organisms” containing coding nucleic acids from more than one taxonomic genus) for purposes that are within TSCA’s jurisdiction  require prior submittal to EPA of a Microbial Commercial Activity Notice (MCAN). These rules include an exemption for R&D activities that in practice is fairly broad and which potentially covers most laboratory or pilot plant activities if conducted in a suitably contained facility or reactor.

By statute, TSCA applies only to new chemicals that are not subject to regulation by other federal agencies, and this same statutory limitation applies to EPA’s biotechnology regulations under this law. For the most part, TSCA jurisdiction includes uses of microorganisms in industrial manufacturing, such as the production of fuels, chemicals, enzymes or any other product that is not regulated as by FDA as a food or food additive, a dietary supplement of any kind, a drug, biologic, or cosmetic, or not regulated by EPA as a pesticide. The TSCA biotech regulations would also cover uses of microorganisms for environmental uses such as bioremediation as well as agricultural uses not regulated as pesticides, including plant inoculants such as those promoting nitrogen fixation, soil amendments and other biofertilizer applications. It is also likely that these regulations would also cover the testing and commercialization of plant biostimulants, a category of products which EPA considers falls outside its pesticide regulations. (EPA has just recently issued an updated draft guidance document for determining which products would be considered as biostimulants and thus not be regulated as pesticides).

Earlier blog posts have described the requirements for determining if an activity qualifies for the broad R&D exemption by virtue of taking place in a “contained structure”. Today’s post deals with EPA regulation of proposed R&D uses of new microorganisms in the open environment, such as agricultural field tests or open-pond uses of modified algae, or other activities that would be deemed not to qualify for the “contained structure” exemption. Such proposed uses would likely require EPA review before the research can be conducted, through the filing of a TERA.  

The TERA process provides an expedited review procedure for small-scale field tests and other outdoor R&D uses of new organisms. Applicants proposing such uses must file a TERA with the EPA at least 60 days in advance of the proposed activity. The data requirements for TERAs are outlined in §§725.255 and 725.260 of the regulations, and these requirements address the key issues which should be considered in environmental risk assessments, as described in the published papers mentioned in an earlier post on the blog. This includes all information in the applicant’s possession pertaining to:

  • phenotypic and ecological characteristics of the microorganism
  • a detailed description of the proposed R&D activity
  • number of microorganisms proposed to be released, and the methods proposed for the release
  • characteristics of the test site(s), including location, geographical, physical, chemical and biological features
  • target organisms (e.g., prey) of the modified microorganism (if any)
  • Information on monitoring, confinement, mitigation, and emergency termination procedures for the microorganisms to be released

EPA is required to review the submitted information and decide whether or not to approve the proposed outdoor R&D activity within 60 days, although the agency could extend the review by an additional 60 days. If EPA determines that the proposed activity does not present an unreasonable risk of injury to health or the environment, it will notify the applicant in writing that the TERA has been approved.  When a TERA is approved, the applicant must carry out the testing under the conditions and limitations described in the TERA application document, but also in accordance with any requirements or conditions included in EPA’s written approval. In most cases, it is likely that EPA will require applicants to conduct some form of monitoring, to detect the possible spread or dispersal of the microorganism from the test site, or to detect any other potential adverse environmental effects. EPA may require collection and submission of other data as well. As specified in §725.270 of the regulations, EPA’s approval is legally binding on the applicant, and violations are subject to civil and criminal penalties. EPA further has the authority to modify or revoke the approval upon receipt of evidence that raises significant questions about the potential risk of the activity.

There has only been limited experience with TERAs since the biotechnology rule was put into place in 1997.   According to EPA’s websites, there have been about 40 TERAs submitted for open environmental use of engineered microorganisms, and all but four of these proposals were approved (those four were either withdrawn or rejected by the agency: further details are not available on the website). The following is a summary of the purposes of the approved TERAS.

From 1998-2015: 30 approved, 3 withdrawn

  • Rhizobia for nitrogen fixation: 5
  • Pesticide research: 3
  • Hazardous waste detection (bioindicators): 13
  • Bioremediation: 2
  • Biofuel research (algae): 5
  • Enzyme production: 2

2016 to date: 6 approved, 1 withdrawn (details not available on the website, due to changes in EPA’s website reporting after the adoption of the 2016 TSCA amendment)

The 5 TERAs for nitrogen fixation all arose in the early 1990s, for a research program that ultimately led to EPA’s approval in September 1997 of limited commercialization of a modified strain of Sinorhizobium meliloti with improved capacity to provide fixed nitrogen to alfalfa. There have apparently been no TERAs since then for microorganisms for improved nitrogen fixation or other biofertilizer applications. It is worth noting that the regulations provided very limited exemptions from TERA reporting for small-scale field testing of modified strains of R. meliloti (now S. meliloti) and Bradyrhizobium japonicum, under 40 CFR Part 725.239, but that these exemptions are extremely narrow and would cover only those proposed tests meeting the stated requirements.

The 3 TERAs which I’ve identified as pesticide research were academic projects from the University of California Riverside in the early 2000s for research on the biology of Alcaligenes xylosoxidans, which was being investigated as a potential biopesticide to control a disease of grapes. I don’t know if this research continued, but these tests were subject to TSCA because they were basic research: if an actual candidate pesticide product had been developed, its field testing would have been subject to EPA regulations under the pesticide law FIFRA and would likely have required obtaining an Experimental Use Permit under those regulations.  

By far the largest category were the 13 TERAs for testing of bioindicators: these were generally microorganisms that had been engineered to contain reporter genes that would be expressed in the presence of hazardous compounds in the environment (e.g. in potentially contaminated soil), triggering a biochemical response that could be detected and quantified. These projects were carried out from 1998 through 2007 by academic and government scientists and one private company, Micro Systems Technologies. It does not appear that this technology has ever been commercialized.

The TERAs in the bioremediation category were submitted in 2013 by the US Army Engineer Research and Development Center and the US Army Corps of Engineers to propose the use of modified strains of Gordonia terrae and Rhodococcus jostii in a field demonstration of bioaugmentation (i.e. bioremediation) to enhance the degradation of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in contaminated groundwater. As I previously discussed in the blog, these TERAs appear to be the first in which approval was granted for release of modified microorganisms into the groundwater (all previous TERAs were for introductions into soil). EPA’s approval included significant monitoring and reporting requirements.

The 5 TERAs for biofuel research constituted a single submission from Sapphire Energy for a field test of modified algae in a biofuel research program. These TERAs were the first to cover the use of modified algae in open-pond reactors, and they proposed the testing of five different intergeneric strains of Scenedesmus dimorphus that had been modified to express metabolism-related genes and a marker gene. The stated purpose of this testing, as summarized on the EPA website, was to (1) evaluate the translatability of the genetically modified strains from the laboratory to an outdoor setting, and (2) to characterize the potential ecological impact (dispersion and invasion) of the genetically-modified microalgae. I described this experiment in more detail in a December 2013 blog post, and Sapphire and their collaborators from the University of California San Diego have published the results of these field tests.

Less is publicly known about the remaining two pre-2016 TERAs, which were two applications submitted and approved in 2015 for the use of Bacillus thuringiensis subspecies Israelensis for what was characterized as “enzyme production”. Since this species is known to have pesticidal properties, this designation is curious, but the EPA website does not include a link to a decision document that might provide more information. It’s likely that this too is a basic research proposal related to the development of a biological or biochemical pesticide.

Similarly, the EPA website gives virtually no information at all about the 7 TERAs submitted after the 2016 TSCA Amendments took effect.  I am in the process of filing a FOIA request to obtain more information on these TERAs and the two 2015 TERAs for enzyme production, and I will report on my findings about these TERAs in a future blog post once I have received that information.

 As a final word, I would note that the TERA process is well-suited to allow the assessment of the potential risks of proposed environmental uses of modified organisms. There are legitimate scientific issues that most observers feel should be addressed in the assessment of such uses, and the TERA process allows outdoor uses of modified microorganisms to take place in a stepwise fashion under appropriate monitoring and agency oversight, to enable environmental risk assessment questions to be addressed with data from actual controlled small-scale environmental use, thus facilitating subsequent risk assessments for larger-scale uses.

D. Glass Associates, Inc. is a consulting company specializing in government and regulatory affairs support for renewable fuels and industrial biotechnology. David Glass, Ph.D. is a veteran of over thirty-five years in the biotechnology industry, with expertise in industrial biotechnology regulatory affairs, U.S. and international renewable fuels regulation, patents, technology licensing, and market and technology assessments. More information on D. Glass Associates’ regulatory affairs consulting capabilities, and links to some of Dr. Glass’s prior presentations on biofuels and biotechnology regulation, are available at www.dglassassociates.com. The views expressed in this blog are those of Dr. Glass and D. Glass Associates and do not represent the views of any other organization with which Dr. Glass is affiliated.